Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Personalised systemic treatment in advanced prostate cancer

ISCO 2023

11 - 12 May 2023

Published: 25 Jan 2024

Views: 39

Rating:

Save

Dr Karim Fizazi - Institute Gustave Roussy, Villejuif, France

Dr Karim Fizazi delivers his presentation at ISCO 2023 on personalised systemic treatment in advanced prostate cancer.

Related Videos

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

ASCO GU 2024: Current best practice for mRCC

Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu

ASCO GU 2024: Current best practice for mRCC ( Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of...

Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )

ASCO GU 2023: Prostate QoL data and apalutamide plus active surveillance

Prof Heather Payne and Dr Jochen Walz

ASCO GU 2023: Prostate QoL data and apalutamide plus active surveillance ( Prof Heather Payne and Dr Jochen Walz )

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy...

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer